A preclinical study showed that MUC28z CAR-T cells, designed to target MUC1, were effective in recognizing and attacking MUC1-positive tumors in mice, significantly reducing tumor size within four days with a prolonged ability to attack cancer cells for up to 81 days after treatment [95]. The gene discussed is MUC1; the disease is neoplasm.